Wang Yonghong, Wu Bei, Tao Yachao, Wang Menglan, Wu Dongbo, Chen Enqiang, Tang Hong
Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
Front Med (Lausanne). 2025 May 9;12:1525719. doi: 10.3389/fmed.2025.1525719. eCollection 2025.
Acute liver failure (ALF) is a rare yet serious clinical syndrome. Recent studies have indicated that stem cells can effectively treat this condition. However, the optimal route for stem cell transplantation in the treatment of ALF remains unclear. This study aims to investigate the most effective transplantation route for stem cell therapy in ALF.
Human umbilical cord mesenchymal stem cells (hUC-MSCs) expressing both luciferase and green fluorescent protein were generated using a lentiviral vector. The hUC-MSCs were transplanted via the tail vein, portal vein, and abdominal cavity. The survival and distribution of the transplanted hUC-MSCs in rats were assessed through imaging and immunofluorescence. Furthermore, the therapeutic effects of hUC-MSCs transplanted via different routes on ALF were compared.
The survival time of hUC-MSCs transplanted via the tail vein and portal vein was shorter compared to those transplanted intraperitoneally. The distribution of hUC-MSCs varied by transplantation route: those injected via the tail vein and portal vein were primarily found in the lungs and liver, respectively, while intraperitoneally transplanted hUC-MSCs predominantly localized in the abdominal cavity. In ALF rats, hUC-MSCs transplanted via the tail vein and portal vein improved survival rates, enhanced liver pathology, and reduced levels of inflammatory cytokines in liver tissue. In contrast, abdominal transplantation of hUC-MSCs showed no significant therapeutic effect.
hUC-MSCs transplanted via the tail vein and portal vein exhibited similar therapeutic effects on ALF; however, abdominal transplantation of hUC-MSCs showed no significant effect.
急性肝衰竭（ALF）是一种罕见但严重的临床综合征。近期研究表明，干细胞可有效治疗该病症。然而，干细胞移植治疗ALF的最佳途径仍不明确。本研究旨在探究干细胞治疗ALF最有效的移植途径。
使用慢病毒载体生成同时表达荧光素酶和绿色荧光蛋白的人脐带间充质干细胞（hUC-MSCs）。将hUC-MSCs经尾静脉、门静脉和腹腔进行移植。通过成像和免疫荧光评估移植的hUC-MSCs在大鼠体内的存活和分布情况。此外，比较经不同途径移植的hUC-MSCs对ALF的治疗效果。
与经腹腔移植的hUC-MSCs相比，经尾静脉和门静脉移植的hUC-MSCs存活时间较短。hUC-MSCs的分布因移植途径而异：经尾静脉注射的主要分布在肺部，经门静脉注射的主要分布在肝脏，而经腹腔移植的hUC-MSCs主要定位于腹腔。在ALF大鼠中，经尾静脉和门静脉移植的hUC-MSCs提高了存活率，改善了肝脏病理状况，并降低了肝组织中炎症细胞因子的水平。相比之下，经腹腔移植hUC-MSCs未显示出明显的治疗效果。
经尾静脉和门静脉移植的hUC-MSCs对ALF表现出相似的治疗效果；然而，经腹腔移植hUC-MSCs未显示出明显效果。
